Robotic partial nephrectomy removes just the tumour and preserves the rest of the kidney — achieving the same cancer control as removing the whole kidney for suitable tumours, while protecting long-term kidney function. Kidney preservation matters for cardiovascular and overall health.
A kidney mass has been found on a scan — likely an incidental discovery on an ultrasound or CT done for another reason. Your urologist has recommended surgery, and specifically, has mentioned partial nephrectomy — removing just the tumour rather than the entire kidney.
This operation is one of the most technically demanding in urological surgery. When performed by an experienced robotic surgeon, it achieves outstanding cancer control while preserving the kidney that would otherwise be removed entirely. Here is what it involves.
1. What is partial nephrectomy?
Partial nephrectomy — also called nephron-sparing surgery — involves surgically removing the tumour from the kidney along with a margin of normal kidney tissue, while leaving the remaining healthy kidney in place. In contrast, radical nephrectomy removes the entire kidney.
For tumours suitable for this approach, partial nephrectomy provides equivalent cancer control to radical nephrectomy — the chance of the cancer recurring is the same whether you remove the tumour alone or the whole kidney. The critical difference is in what happens to your kidney function.
2. Why kidney preservation matters
Losing one kidney reduces your total kidney function (eGFR — estimated glomerular filtration rate) by approximately 25–40%. While most people can live a normal life with one kidney, reduced kidney function has real consequences:
- Cardiovascular risk: Lower eGFR is independently associated with higher rates of cardiovascular disease, coronary artery disease, and hypertension.
- Risk of dialysis: If the remaining kidney is ever injured — by infection, stone, or another tumour — dialysis may become necessary. With two functioning kidneys, there is a reserve.
- Drug dosing and medication safety: Many medications require dose adjustment in reduced kidney function, limiting future treatment options.
- Quality of life: Chronic kidney disease of any degree reduces long-term wellbeing and increases healthcare utilisation.
European Association of Urology (EAU) guidelines recommend partial nephrectomy over radical nephrectomy for all T1 tumours (under 7 cm) where it is technically feasible. This is not a minor preference — it is based on strong evidence that kidney preservation improves long-term survival by reducing cardiovascular mortality.
3. Who is a candidate for partial nephrectomy?
Partial nephrectomy is recommended for most T1 tumours (under 7 cm, confined to the kidney). The decision depends on tumour factors:
- Small (under 4 cm) — easiest cases
- Exophytic — growing outward from kidney surface
- Polar location — at the top or bottom pole
- Not involving the renal collecting system
- Not in the renal hilum (central vessels)
- Endophytic — deeply embedded within kidney tissue
- Central or hilar location — near main vessels
- Involving the collecting system
- Multiple tumours in the same kidney
- Very large (>5 cm) — technically demanding
Tumour complexity is scored using the R.E.N.A.L. or PADUA nephrometry scoring systems, which predict operative difficulty and guide surgeon planning. Even complex tumours can often be managed with partial nephrectomy in experienced robotic hands.
4. The robotic approach
Robotic partial nephrectomy is performed through 4–5 small keyhole incisions (8–12mm). The da Vinci robotic system provides 3D magnification and articulating instruments that allow precise, millimetre-level dissection around the tumour.
The kidney is accessed retroperitoneally (behind the peritoneum) or transperitoneally (through the abdominal cavity), depending on tumour location and surgeon preference. The advantages of the robotic approach over conventional laparoscopic partial nephrectomy include:
- Enhanced 3D visualisation in the narrow surgical field
- Tremor-free instrument control for precise tumour excision
- Articulating needle drivers for faster, more precise sutured repair of the kidney
- Significantly shorter warm ischaemia time compared to laparoscopic approaches
5. Warm ischaemia time — the key technical challenge
During tumour removal, the blood supply to the kidney must be temporarily clamped — otherwise the kidney bleeds uncontrollably during excision. The period during which the kidney is without blood flow is called the warm ischaemia time (WIT).
Kidney tissue begins to sustain ischaemic injury after approximately 20–25 minutes without blood flow. Beyond 30 minutes, there is measurable long-term damage to kidney function. The surgeon's goal is to complete tumour removal and kidney repair within this window.
For selected exophytic tumours, experienced surgeons can perform partial nephrectomy without clamping the renal artery at all — zero ischaemia time. This requires confident haemostatic technique and is increasingly preferred for peripheral tumours where it is technically feasible.
6. What to expect after surgery
Hospital stay: 2–3 days
A small drain from the kidney area is typically left in place and removed on day 2. Pain is generally well controlled with regular analgesia. Blood tests to check kidney function are done on day 1.
Weeks 1–2: Rest at home
Avoid any lifting or strenuous activity. Short walks are encouraged. Some discomfort around the port sites and flank is expected and managed with oral analgesia.
Weeks 2–4: Gradual return to activity
Light activity and desk work can resume. Driving is cleared when you are off strong painkillers and can perform an emergency stop safely — typically at 2–3 weeks.
4–6 weeks: Follow-up and pathology review
Outpatient appointment to review final pathology (confirming tumour type, grade, and whether surgical margins are clear). Blood tests check kidney function. CT or MRI surveillance schedule is planned.
7. Cancer control after partial nephrectomy
For T1 tumours, partial nephrectomy achieves equivalent cancer control to radical nephrectomy (complete kidney removal). Local recurrence rates are under 3% in experienced centres. The 5-year cancer-specific survival for pT1a disease (tumours under 4 cm) exceeds 97%.
Follow-up imaging — typically contrast-enhanced CT or MRI — is performed at specific intervals after surgery to monitor for recurrence in the remaining kidney and check for metastatic disease. The schedule depends on tumour grade and stage.
- Am I a candidate for partial nephrectomy — or does the tumour location require full kidney removal?
- What is my tumour's RENAL or PADUA score — and what does this mean for complexity?
- What warm ischaemia time do you expect — and is off-clamp feasible?
- How many robotic partial nephrectomies do you perform per year?
- Should I have a biopsy before surgery — to confirm this is malignant?
- What follow-up imaging will I need — and for how long?
This article is for general patient education about robotic partial nephrectomy. Surgical eligibility depends on individual tumour and patient factors. Discuss your specific situation in detail with an experienced urological surgeon.